The program will enable Partners HealthCare Center for Personalized Genetic Medicine (PCPGM) to develop new molecular diagnostic assays based on biomarkers discovered within Partners HealthCare entities.

The discovered tests will operate on Luminex‘s proprietary xMAP testing platform.

Under the terms of the agreement, Luminex and PCPGM will evaluate opportunities for new assays which will be developed and validated in the PCPGM’s CLIA-certified Laboratory for Molecular Medicine.

Partners HealthCare PCPGM’s Laboratory for Molecular Medicine director Heidi Rehm said the collaboration with Luminex represents an important step forward in furthering Partners HealthCare Center for Personalized Genetic Medicine’s mission to bridge the gap between research and clinical medicine.

"Luminex’s xMAP technology provides an ideal platform for Partners HealthCare to translate novel biomarker discoveries into tests and accelerate adoption of new molecular tests to provide the best clinical care for patients," Rehm said.